Market Overview

UPDATE: Stifel Nicolaus Raises PT to $38 on Align Technology on Trial Outlook

Share:
Related ALGN
Morgan Stanley Lists Top SMID Stocks To Buy And Sell Headed Into 2017
Align's New Direct-To-Consumer Focus Earns It A Higher Price Target From Stifel
Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q4 2016 Update (Seeking Alpha)

Stifel Nicolaus reiterated its Buy rating on Align Technology (NASDAQ: ALGN) and raised the price target from $32.00 to $38.00.

Stifel Nicolaus said, "Align's patent infringement trial against ClearCorrect is scheduled to begin today. … With the limited information contained in the public filings, Mr. Lavelle acknowledged it would be difficult to handicap the potential outcome of the trial. That said, he seems to think Align has a strong position, given the broad claims covered by the seven patents being asserted against ClearCorrect as well as Align's prior success with some of these same patents in prior litigation with OrthoClear. Additionally, two of the seven patents were recently re-validated by the United States Patent and Trademark Office (USPTO), which likely mitigates ClearCorrect's ability to claim the patents are invalid."

Align Technology closed at $31.90 on Friday.

Latest Ratings for ALGN

DateFirmActionFromTo
Nov 2016Stifel NicolausMaintainsBuy
Oct 2016BairdDowngradesOverweightNeutral
Jul 2016Stifel NicolausMaintainsBuy

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALGN)

View Comments and Join the Discussion!